Insights

See individual biographies for licensure details

Total: 11 results

Psychedelic Drug Development Takes Center Stage – Do You Have What it Takes to Bring a Psychedelic Drug to Market?

August 5, 2026

FDA Leadership Provides Revised Priorities at Reagan-Udall Foundation Annual Board of Directors Meeting

July 23, 2026

FDA Commissioner – Year in Review … What’s Next?

July 14, 2026

DEA Taking Steps to Issue Temporary Scheduling Order for Kratom-Based Products Including High Levels of 7-OH and 7-OH-Related Synthetic Components

July 7, 2026

FDA’s First New Sunscreen Active Ingredient in Decades: Regulatory Exclusivity and Commercial Implications

June 29, 2026

Operation TrialBlazer Launches to Restore U.S. Leadership to Clinical Trials

June 24, 2026

FDA Reports Meeting Year One Goals for Reducing Animal Drug Testing

June 8, 2026

U.S. Supreme Court Reinstates Skinny Labeling Induced Infringement Standard

June 5, 2026

U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels

May 21, 2026

Congress Enacts Long-Awaited Fix to Orphan Drug Exclusivity in 2026 Consolidated Appropriations Act

February 19, 2026

Q1/Q2 Sameness Transparency Provision Expected to Save $800 Million Over 10 Years

February 11, 2026